Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lauren E. Bufe"'
Supplementary Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Autor:
Kwok-Kin Wong, Nathanael S. Gray, David A. Barbie, Geoffrey I. Shapiro, Haribabu Arthanari, Norman E. Sharpless, W. Nicholas Haining, Jerome Ritz, Gordon J. Freeman, Sangeetha Palakurthi, Raphael Bueno, Genevieve M. Boland, Viswanath Gunda, Sareh Parangi, Jochen H. Lorch, William G. Richards, Jay C. Strum, Patrick J. Roberts, Eric Haines, Amanda J. Rode, Megan E. Cavanaugh, Ting Chen, Peng Gao, Hua Zhang, Yanxi Zhang, Annan Yang, Lauren E. Bufe, Max M. Quinn, Ashley A. Merlino, Patrick H. Lizotte, John E. Bisi, Jessica A. Sorrentino, Grit S. Herter-Sprie, Chensheng W. Zhou, Michaela Bowden, Cloud P. Paweletz, Elena Ivanova, Amir R. Aref, Hongye Liu, Wei Huang, Sandeep Chhabra, Kathleen Yates, Ruben Dries, Shuai Li, Russell W. Jenkins, Eric S. Wang, Jiehui Deng
Figure S1. Characterization of cells and CDK4/6 inhibitors; Figure S2. CDK6 phosphorylates serine residues of the regulatory domain of NFAT4 (NFATc3); Figure S3. Analysis of lung tumor immune infiltrates after CDK4/6 inhibition from KrasG12D (Kras),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22a01c7e72b06ed917fff29065c873f6
https://doi.org/10.1158/2159-8290.22531849.v1
https://doi.org/10.1158/2159-8290.22531849.v1
Autor:
Paw Osathanugrah, George Kasotakis, Lauren E. Bufe, Neerav Dharia, Zachary Breed, Joseph P. Mizgerd, Manuel D. Galvan, Daniel G. Remick
Publikováno v:
Journal of Surgical Research. 220:206-212
Background Acute lung injury and respiratory distress syndrome is characterized by uncontrolled inflammation of the lungs after a severe inflammatory stimulus. We have previously demonstrated an ameliorated syndrome and improved survival in mice with
Autor:
Khanh T. Do, Shengwu Liu, Shuai Li, Kwok-Kin Wong, Christine Ng, Josephine Hai, Lauren E. Bufe, Xiaoen Wang, Ming-Sound Tsao, Ting Chen, Geoffrey I. Shapiro
Publikováno v:
Clinical Cancer Research. 23:6993-7005
Purpose: KRAS-activating mutations are the most common oncogenic driver in non–small cell lung cancer (NSCLC), but efforts to directly target mutant KRAS have proved a formidable challenge. Therefore, multitargeted therapy may offer a plausible str
Autor:
Jochen H. Lorch, Jerome Ritz, Patrick J. Roberts, Geoffrey I. Shapiro, Max M. Quinn, Michaela Bowden, Eric S. Wang, Gordon J. Freeman, John E. Bisi, David A. Barbie, Megan E. Cavanaugh, Sandeep Chhabra, Shuai Li, Hua Zhang, Chensheng W. Zhou, Eric Haines, Cloud P. Paweletz, Ruben Dries, Russell W. Jenkins, Amir Reza Aref, Hongye Liu, Genevieve M. Boland, Nathanael S. Gray, Jessica A. Sorrentino, Ting Chen, W. Nicholas Haining, Norman E. Sharpless, Patrick H. Lizotte, Yanxi Zhang, Lauren E. Bufe, Viswanath Gunda, Annan Yang, Raphael Bueno, Ashley A. Merlino, Jiehui Deng, Kathleen B. Yates, Peng Gao, Amanda J. Rode, Wei Huang, Sareh Parangi, Grit S. Herter-Sprie, Kwok-Kin Wong, Haribabu Arthanari, William G. Richards, Sangeetha Palakurthi, Jay C. Strum, Elena Ivanova
Publikováno v:
Cancer discovery. 8(2)
Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the efficacy of existing immunotherapies, we screened for small molecules capable of increasing the a